The efficacy and mechanisms of action of N-acetylcysteine as an adjunct treatment for first episode psychosis.

Phase 3

Recruiting

• Conditions: First episode psychosis; Mental Health - Psychosis and personality disorders

• Registration Number: ACTRN12618000413224
• Lead Sponsor: Orygen, The National Centre of Excellence in Youth Mental Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-03-21
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 162

Inclusion Criteria

i.Aged 15 to 25 years at time of study enrolment;
ii.Treatment stability: at least two weeks of stability in the use of primary medication
(e.g., anti-psychotic medications)
iii.Within their first three months of admission to the Early Psychosis Prevention and
Intervention Centre (EPPIC); and
iv.Capacity to consent to the study and comply with study procedures.

Exclusion Criteria

i.Previous episode of psychosis or previously been treated with an anti-psychotic
prior to entry to the program;
ii.Known or suspected clinically relevant systemic medical disorder;
iii.Females who are pregnant or lactating;
iv.Prior sensitivity or allergy to NAC;
v.Currently enrolled in another research study
vi.Inability to comply with either the requirements of informed consent or the treatment
protocol; and/or
vii.Non-fluency in English

Study & Design

• Study Type: Interventional
• Study Design: Not specified